Concepedia
Statistics
Publications
14
Citations
367
H-Index
11
Active since
2010
Affiliations
Ascendis Pharma (Denmark)(Current)
Cedars-Sinai Medical Center
Biogen (United States)
Astellas Pharma (United States)
EXPORTech (United States)
Ken O’Day is an author at Ascendis Pharma (Denmark) specializing in cost-effectiveness analysis, pharmacy, and pharmacoeconomics.
Publications per year
2010–2020
Cost-effectiveness of Coronary CT Angiography versus Myocardial Perfusion SPECT for Evaluation of Patients with Chest Pain and No Known Coronary Artery Disease
James K. Min, Amanda Gilmore, Matthew J. Budoff et al. · Radiology · 2010 · 112 citations
Medicine, Cardiology, Internal Medicine +17
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis
Ken O’Day, Kellie Meyer, Ross M. Miller et al. · Journal of Medical Economics · 2011 · 46 citations
Pharmacy, Pharmacoeconomics, Pharmacotherapy +17
Economic and Humanistic Consequences of Preventable Bladder Tumor Recurrences in Nonmuscle Invasive Bladder Cancer Cases
Cheryl T. Lee, Daniel A. Barocas, Denise Globe et al. · The Journal of Urology · 2012 · 34 citations
Medicine, Oncology, Urology +17
Cost-effectiveness of diagnostic evaluation strategies for individuals with stable chest pain syndrome and suspected coronary artery disease
James K. Min, Amanda Gilmore, Erica C. Jones et al. · Clinical Imaging · 2017 · 28 citations · Full text
Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
Ken O’Day, Krithika Rajagopalan, Kellie Meyer et al. · ClinicoEconomics and Outcomes Research · 2013 · 22 citations · Full text
Pharmacy, Pharmacoeconomics, Psychiatry +17
1–5 of 14